Hogarth P J, Hewinson R G, Vordermeier H M
TB Research Group, Veterinary Laboratories Agency-Weybridge, New Haw, Addlestone, Surrey, UK.
J Pharm Pharmacol. 2006 Jun;58(6):749-57. doi: 10.1211/jpp.58.6.0005.
Bovine tuberculosis caused by Mycobacterium bovis remains an economically important problem in Great Britain with potential zoonotic consequences, and the incidence is rising exponentially. In 1997 an independent scientific review recommended that the best option for disease control in Great Britain was the development of a cattle vaccine. Bovine tuberculosis remains a significant problem in countries of the developing world. Indeed, more than 94% of the world's population live in countries in which the control of bovine tuberculosis in buffalos or cattle is limited or absent. Effective vaccination strategies would have a major impact in countries that cannot afford expensive test and slaughter-based control strategies. Here, we present a review of progress toward that goal, and discuss how this progress has shaped our research strategy for the development of a vaccine.
由牛分枝杆菌引起的牛结核病在英国仍然是一个具有重要经济意义且存在潜在人畜共患病后果的问题，并且发病率正在呈指数级上升。1997年，一项独立的科学评估建议，在英国控制该疾病的最佳选择是研发一种牛用疫苗。牛结核病在发展中国家仍然是一个重大问题。事实上，世界上超过94%的人口生活在水牛或牛的牛结核病控制有限或缺失的国家。有效的疫苗接种策略将对那些无力承担基于检测和屠宰的昂贵控制策略的国家产生重大影响。在此，我们对朝着该目标取得的进展进行综述，并讨论这一进展如何塑造了我们研发疫苗的研究策略。
